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Abstract
Background: Neuron-specific enolase (NSE) and S100
protein are implicated in several brain injuries, includ-
ing stroke. Our objective was to analyze the temporal
profile and the clinical significance of NSE and S-100
in acute ischemic (IS) and intracerebral hemorrhage
(ICH).
Methods: We studied 224 patients with IS and 44
patients with ICH. Computerized tomography (CT)
scans were performed to assess infarct volume.
Stroke severity was evaluated using the National
Institute of Health Stroke Scale (NIHSS), and function-
al outcome at 3 months with the modified Rankin
Scale (mRS). Serum NSE and S100 protein were
measured using an electrochemiluminescence-
immunoassay.
Results: Peak values were found at 72 h for NSE and
at 24 h for S100 in IS. For ICH, peak values were found
at 24 h for both NSE and S100. At these time intervals
S100 and NSE correlated with the NIHSS score and
were independently associated with poor outcome.
Conclusions: High serum NSE and S100 are associ-
ated with poor outcome in IS, and high serum NSE is
associated with poor outcome in ICH. These findings
suggest the potential utility of NSE and S100 as prog-
nostic markers for acute stroke.
Clin Chem Lab Med 2009;47:1513–8.
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Introduction
In recent years, biochemical markers of brain damage
have gained particular attention. The study of mole-
cular markers associated with stroke has proven to be
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Neurologı́a, Hospital Clı́nico Universitario, 15706 Santiago
de Compostela, Spain
Phone: q34 981 951348, Fax: q34 981 951098,
E-mail: jose.castillo@usc.es
Received May 6, 2009; accepted August 21, 2009;
previously published online October 28, 2009
useful for both diagnostic and prognostic purposes.
Molecular markers of neurotoxicity (1) and inflam-
mation (2, 3) have been associated with early neuro-
logical deterioration (4), infarct volume, hemorrhagic
transformation (5, 6) and other clinical variables.
Protein S100 is a dimeric acidic calcium binding
protein whose isoforms S100 and S100A1b are found
predominantly in glial cells and Schwann cells (7–9).
This protein performs intracellular functions, such as
modulation of cytoskeleton proteins, regulation of cel-
lular cycles, and extracellular functions, all of which
are concentration dependent. Neuron-specific enolase
(NSE) is the neuronal form of the intracytoplasmic
glycolitic enzyme enolase. The gg isoform is found in
neurons, as well as in cells with neuroendocrine dif-
ferentiation. This dimeric enzyme has a molecular
weight of 78 kDa and catalyzes the interconversion of
2-phosphoglycerate and phosphoenolpyruvate (10).
Since NSE is not secreted physiologically, an increase
in serum and cerebrospinal fluid (CSF) concentrations
is considered to be a marker for neuronal cell dam-
age. Several studies have been performed to investi-
gate its potential role as a peripheral biochemical
marker for neuronal injury involving reactive gliosis,
astrocytic death and/or blood-brain-barrier dysfunc-
tion (11).
Some studies have found correlation between NSE
and S100 serum values and brain damage following
stroke. However, the temporal profile of these bio-
markers in serum is not clear because different peak
values are found in the literature (12). In addition,
there is some controversy regarding the best time-
point for measuring NSE and S100 in serum. Different
investigators describe the correlation between these
biomarkers and clinical variables using various times
(13–19).
We investigated the relationship between the
temporal profile of proteins S100 and NSE and their
correlation with clinical variables and functional out-
come in a large series of patients with ischemic stroke
(IS) and intracerebral hemorrhage (ICH).
Materials and methods
Study population and patients characteristics
Between May 2004 and September 2005, 355 patients with a
first time stroke in the anterior territory of -12 h duration,
and previously independent with respect to their daily living
activities, were prospectively evaluated for inclusion.
Patients with chronic inflammatory diseases (ns7), severe
hepatic (ns4) or renal (ns3) diseases, hematological dis-
eases (ns3), cancer (ns5), or infectious disease within
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15 days prior to admission (ns11) and patients included in
other clinical trials (ns41) were excluded. Five patients did
not agree to participate in the study and eight patients were
lost to follow-up. Thus, a total of 224 patients (mean age
70.2 years, mean time from onset 7.2 h) with IS, and 44
patients (mean age 61.5 years, mean time from onset 4.7 h)
with ICH were included.
This study was approved by the Ethics Committee of our
hospital and was in accordance with the Helsinki Declaration
of 1975, as revised in 1983. Informed consent was obtained
from patients or their relatives.
Clinical variables
All patients were admitted in the Acute Stroke Unit and treat-
ed by the same unit staff according to the Guidelines of the
Cerebrovascular Diseases Study Group of the Spanish Soci-
ety of Neurology (20). Medical history, potential vascular risk
factors, blood and coagulation testing, 12-lead ECG, chest
radiography, and carotid ultrasonography were performed at
admission.
Stroke severity was assessed by a certified neurologist
using the National Institute of Health Stroke Scale (NIHSS)
at admission, 1, 3, 7"1 and 90"7 days from onset of symp-
toms (21, 22). Functional outcome was evaluated at 90 days
from onset of symptoms using the modified Rankin Scale
(mRS) (22).
Neuroimaging studies
Computerized tomography (CT) scans were performed at
admission and between days 4 and 7 of hospitalization. Early
CT signs of infarction were evaluated upon admission, and
infarct and ICH volume were assessed using the second CT-
scan. Infarct and ICH volume were calculated using the radio-
graphic plate with the formula 0.5=a=b=c (where a is the
maximal longitudinal diameter, b is the maximal transverse
diameter perpendicular to a, and c is the number of 10 mm
slices from the site of infarct or hemorrhage).
All CT scans were evaluated by neuroradiologists blinded
to the clinical and biochemical data.
Outcome variables
The primary endpoint was poor functional outcome defined
as mRS )2 at 90 days from onset of symptoms.
Laboratory tests
Blood samples, drawn from all patients at admission, 24 and
72 h, were collected in test tubes, centrifuged at 3000 g for
10 min, and immediately frozen and stored at –808C. Serum
NSE and S100 (Isoforms S100 and S100A1b) concentrations
were measured with an electrochemiluminescence immu-
noassay using the ELECSYS 2010 (Roche Diagnostics, Penz-
berg, Germany). This technique is based on a double
sandwich assay using antibodies bound with ruthenium
(luminescent label). Sensitivity of the method is 0.05 ng/mL
for NSE and 0.005 mg/L for S100. The inter-assay variability
was 4.2% for NSE and 2.4% for S100 determinations.
Determinations were performed in an independent
laboratory blinded to clinical and neuroimaging data.
Statistical analysis
Results are expressed as percentages for categorical
variables and as means (SD) or medians wquartilesx for con-
tinuous variables. Proportions were compared using the x2-
test. Student’s t-test or the Mann-Whitney test were used to
compare continuous variables between groups. Spearman
analysis was used for bivariate correlations.
The influence of the molecular profile of NSE and S100
protein on functional outcome was assessed using logistic
regression analysis after adjusting for main baseline
variables related to outcome in the univariate analyses (enter
approach and probability of entry p-0.05). Results were
expressed as adjusted odds ratios (OR) with the correspond-
ing 95% confidence intervals (95% CI).
Results
Baseline clinical characteristics, vascular risk factors,
stroke subtype, biochemical parameters, neuroimag-
ing findings and molecular markers in patients with
IS or ICH are shown in Table 1. Poor outcomes (mRS
)2) were found in 39.3% of patients with IS and in
59.1% of patients with ICH. For patients with IS, peak
values were seen at 72 h for NSE (10.4 ng/mL) and at
24 h for S100 (0.15 mg/L). However, for subjects with
ICH, peak values were seen at 24 h for both NSE
(13.5 ng/mL) and S100 (0.13 mg/L) (Figure 1). At these
time intervals, S100 and NSE concentrations correlat-
ed with greater NIHSS scores at the same time. In
fact, NSE serum concentrations correlated with
NIHSS for IS at 72 h (rs0.319, p-0.0001) and at 24 h
for ICH (rs0.407, p-0.0001). Serum concentrations of
S100 were associated with NIHSS for IS (rs0.558) and
ICH (rs0.607) at 24 h (all p-0.0001). In addition, con-
centrations correlated with infarct volumes deter-
mined between the 4th and 7th days (NSE serum
concentrations at 72 h: Spearman coefficient 0.456,
ps0.002; S100 serum concentrations at 24 h: Spear-
men coefficient 0.714, p-0.0001).
Table 2 shows the temporary profile of molecular
markers in patients with poor or good functional out-
come in IS or ICH. Patients with IS who had a poor
outcome showed greater serum concentrations of
NSE at 72 h and S100 at 24 h (13.7 w8.2, 15.9x vs. 8.9
w5.3, 11.6x ng/mL; p-0.0001) and (0.28 w0.12, 0.46x vs.
0.11 w0.07, 0.28x mg/L; p-0.0001), respectively. Also,
serum concentrations of NSE at 24 h were signifi-
cantly greater for ICH patients with poor outcome
compared to those with good outcome (17.8 w13.4,
21.5x vs. 11.6 w8.1, 14.2x ng/mL; p-0.0001).
After adjustment for variables that were significant
in the univariate analysis, NSE at 72 h (OR, 2.9; 95%
CI, 1.3–8.5; ps0.032) and S100 at 24 h in patients with
IS were independent markers for poor outcome (OR,
4.7; 95% CI, 2.5–7.6; p-0.0001). Also, after adjust-
ment for variables that were significant in the univa-
riate analysis, NSE at 24 h in ICH was independently
associated with poor outcome (OR, 2.6; 95% CI,
1.9–15.6; ps0.038).
Discussion
Peripheral markers of injury to the central nervous
system may help in the diagnosis and management
of IS (23). This prospective study evaluates the rela-
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Table 1 Baseline clinical characteristics, vascular risk factors, stroke subtype, biochemical parameters, neuroimaging findings





Age, years 70.2 (5.6) 61.5 (12.7)
Male, % 69.6 59.1
Time from stroke onset, h 7.2 (4.5) 4.7 (2.9)
History of hypertension, % 52.2 60.0
History of diabetes, % 17.3 14.8
History of dyslipemia, % 23.3 20.4
Smoking habit, % 15.4 15.0
Clinical characteristics
NIHSS at admission 9 w5, 15x 12 w6, 16x
NIHSS at 1 day 6 w2, 12x 8 w3, 13x
NIHSS at 3 days 4 w1, 11x 7 w1, 15x
Early neurological deterioration, % 18.7 29.5
Stroke subtype (TOAST)
Atherothrombotic, % 13.3 –
Cardioembolic, % 37.8 –
Lacunar, % 11.0 –
Undetermined, % 34.4 –
Others, % 3.3 –
Dead patients in the first 3 months, % 2.1 11.0
mRS )2 at 3 months, % 39.3 59.1
Neuroimaging findings
Infarct or ICH volume, cm3 18 w0–54x 19 w10–30x
Biochemistry and vital signs
Mean systolic blood pressure, mm Hg 149.0 (22.1) 180.1 (30.2)
Mean diastolic blood pressure, mm Hg 79.2 (14.6) 98.1 (20.3)
Glucose concentration, mmol/L 67.72 w56.06–81.04x 67.16 w61.61–89.37x
Temporal profile of molecular markers
NSE serum concentration at admission, ng/mL 8.6 w5.7, 10.9x 8.9 w7.4, 12.2x
NSE serum concentration at 24 h, ng/mL 9.1 w6.9, 10.9x 13.5 w9.7, 15.1x
NSE serum concentration at 72 h, ng/mL 10.4 w7.3, 13.6x 10.5 w6.7, 15.1x
S100 serum concentration at admission, mg/L 0.07 w0.05–0.11x 0.08 w0.07–0.15x
S100 serum concentration at 24 h, mg/L 0.15 w0.07, 0.32x 0.13 w0.06, 0.27x
S100 serum concentration at 72 h, mg/L 0.06 w0.04–0.16x 0.12 w0.09–0.23x
Data are given as percentages for categorical variables and as means (SD) or medians wquartilesx for continuous variables.
Figure 1 Temporal profile (admission, 24 h and 72 h) of serum concentrations of NSE and S100 protein in acute ischemic
and hemorrhagic stroke.
Boxplots show median values (horizontal lines inside the box), quartiles (box boundaries), and the largest and smallest
observed values (lines drawn from the end of the box).
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Table 2 Temporal profile of molecular markers in patients with poor or good outcome classified in ischemic or hemorrhagic
stroke.
Good outcome Poor outcome p-Value
(mRSF2) (mRS)2)
Ischemic stroke ns136 ns88
NSE serum concentration at admission 8.5 w5.2, 11.9x 9.2 w5.3, 12.1x 0.067
NSE serum concentration at 24 h 8.5 w5.1, 11.6x 10.8 w5.2, 13.4x 0.057
NSE serum concentration at 72 h 8.9 w5.3, 11.6x 13.7 w8.2, 15.9x -0.0001
S100 serum concentration at admission 0.06 w0.05, 0.12x 0.08 w0.05, 0.15x 0.064
S100 serum concentration at 24 h 0.11 w0.07, 0.28x 0.28 w0.12, 0.46x -0.0001
S100 serum concentration at 72 h 0.06 w0.03, 0.17x 0.06 w0.05, 0.14x 0.832
Hemorrhagic stroke ns18 ns26
NSE serum concentration at admission 7.4 w6.5, 10.8x 9.3 w7.2, 13.6x 0.052
NSE serum concentration at 24 h 11.6 w8.1, 14.2x 17.8 w13.4, 21.5x -0.0001
NSE serum concentration at 72 h 8.2 w5.5, 14.0x 12.2 w5.9, 18.6x 0.061
S100 serum concentration at admission 0.08 w0.06, 0.14x 0.08 w0.05, 0.15x 0.369
S100 serum concentration at 24 h 0.12 w0.05, 0.23x 0.14 w0.09, 0.31x 0.174
S100 serum concentration at 72 h 0.06 w0.02, 0.21x 0.07 w0.02, 0.30x 0.805
Data are given as medians wquartilesx.
tionship between serum concentrations of NSE and
S100 (Isoforms S100 and S100A1b) and functional
outcomes in patients with IS or ICH. High serum con-
centrations of NSE at 72 h and S100 at 24 h following
onset of stroke were associated with poor functional
outcome in patients with IS. High serum concentra-
tions of NSE 24 h following onset of stroke were asso-
ciated with poor functional outcome in patients with
ICH. In addition, at these time intervals we found
correlation with molecular markers and infarct or
hemorrhage volume.
We found that NSE at 72 h and S100 at 24 h for IS
and NSE at 24 h for ICH are associated with functional
outcome. Concentrations of these biomarkers at other
time intervals did not show prognostic value. This
demonstrates the importance of serial determinations
of these biomarkers. Prognostic information is partic-
ularly relevant for estimating the risk of severe com-
plications, and how intensive the rehabilitation
program needs to be for individual patients. Several
clinical scores are known to be predictive of outcome,
but blood markers might also contain additional prog-
nostic information. Because development of ischemia
is a dynamic process, changes in NSE and S100 dur-
ing the first 72 h following onset of stroke are relevant
to outcome. We have demonstrated that NSE at 72 h
and S100 at 24 h in patients with IS, and NSE at 24 h
for patients with ICH are associated with poor func-
tional outcome at 3 months. Thus, these biomarkers
could provide additional information about the out-
come of stroke patients.
The mean values of NSE in our laboratory were
relatively low when compared to published cut-offs
for normal values (12.5 ng/mL). It is known that meas-
urement of NSE with the ELECSYS results in lower
systematically concentrations (;9%). However, this
method presents some advantages with respect to
other ELISA methods. The ELECSYS has a low intra-
and interassay coefficient of variation (0.7%–5.3%),
reportable range between 0.0 and 320 ng/mL and a
short incubation time of 18 min (24). In addition, in
the study by Wunderlich et al. (19), the concentrations
of NSE assessed with the LIAISON kit (DiaSorin, Diag-
nostica, Dietenzbach, Germany) exceeded the cut-off
value of 12.5 ng/mL in 13% of stroke patients only,
during the first 24 h.
Comparing the association of these molecular
markers with functional outcome, we found that sim-
ilar studies conducted by Jauch et al. (25) on patients
with acute IS showed that the strongest correlation
between NSE and S100 concentrations and outcome
was seen in samples drawn within 24 h from onset of
stroke. Likewise, our results are in agreement with
those reported by Martens et al. (26) who used serum
concentrations of S100 protein at 24 h as a marker for
cerebral damage in patients affected with global cer-
ebral ischemia. However, our finding contrasts with
the study of Cunningham et al. (27) who reported
correlation between NSE concentrations and infarct
volume, but not with outcome. This study evaluated
a total of 24 patients only, which might explain the
lack of an association with outcome. Other studies
have found a correlation between S100 concentra-
tions and outcome in patients with subarachnoid
hemorrhage (28, 29).
The analysis of the expression profile of these
proteins revealed that the highest concentrations for
NSE and for S100 were seen at 24 h in patients with
ICH, whereas, patients with IS showed highest con-
centrations of NSE and S100 at 72 h and 24 h, respec-
tively. These results are in agreement with previous
studies that show a peak value at 24 h for NSE con-
centrations in patients with IS, as well as those treat-
ed with tissue plasminogen activator (tPA) (30).
However, other investigators report peak concentra-
tions 2–3 or more days following onset (17, 30, 31).
In this prospective study, we analyzed the relation-
ship between serum concentrations of NSE and S100
proteins with neurological and functional outcomes in
more than 200 patients with IS and more than 40
patients with ICH. Other studies have been carried out
using different evaluation scales for functional out-
come, such as the Glasgow Outcome Score, studying
shorter evolution times, differentiating the infarcts by
territories and using smaller number of patients.
These variables may explain why many of the results
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reported previously could be different with those
reported in our study (32).
In summary, high serum concentrations of NSE at
72 h and S100 at 24 h following stroke are associated
with poor outcome in patients with IS. High serum
concentrations of NSE at 24 h following stroke are
associated with poor outcome in patients with ICH.
These findings suggest the potential prognostic utility
of these markers for acute stroke.
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1. Castillo J, Dávalos A, Naveiro J, Noya M. Neuroexcitatory
amino acids and their relation to infarct size and neuro-
logical deficit in ischemic stroke. Stroke 1996;27:1060–5.
2. Castillo J, Leira R. Predictors of deteriorating cerebral
infarct: role of inflammatory mechanisms. Would its early
treatment be useful? Cerebrovasc Dis 2001;11:40–8.
3. Castellanos M, Castillo J, Garcı́a MM, Leira R, Serena J,
Chamorro A, et al. Inflammation-mediated damage in pro-
gressing lacunar infarctions a potential therapeutic target.
Stroke 2002;33:982–7.
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